Showing results (201-210 of 236) with videos related to
Sort By:
Pageof 24
Journal of Cellular Biochemistry. Supplement|January 1, 1995
Development of inhibitors of protein farnesylation as potential chemotherapeutic agentsN E Kohl, M W Conner, J B Gibbs, et al.Organic Letters|March 27, 2001
3,8-Diazabicyclo[3.2.1]octan-2-one peptide mimetics: synthesis of a conformationally restricted inhibitor of farnesyltransferaseC J Dinsmore, J M Bergman, M J Bogusky, et al.Transplantation|January 9, 1998
Parvovirus B19 infection-related complications in renal transplant recipients: treatment with intravenous immunoglobulinA Moudgil, H Shidban, C C Nast, et al.Journal of Neurology, Neurosurgery, and Psychiatry|December 24, 2011
Relationship between chronic demyelination of the optic nerve and short term axonal lossA Klistorner, R Garrick, M Paine, et al.European Journal of Neurology|August 12, 2017
Progression of retinal ganglion cell loss in multiple sclerosis is associated with new lesions in the optic radiationsA Klistorner, E C Graham, C Yiannikas, et al.Current Opinion in Chemical Biology|August 1, 1997
Farnesyltransferase inhibitors versus Ras inhibitorsJ B Gibbs, S L Graham, G D Hartman, et al.British Journal of Pharmacology|January 1, 1990
L-662,583 is a topically effective ocular hypotensive carbonic anhydrase inhibitor in experimental animalsM F Sugrue, P Gautheron, P Mallorga, et al.Molecular and Cellular Biology|June 1, 1994
Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeletonG C Prendergast, J P Davide, S J deSolms, et al.Journal of Medicinal Chemistry|July 23, 1993
Sulfonylmethanesulfonamide inhibitors of carbonic anhydraseT H Scholz, J M Sondey, W C Randall, et al.Bioorganic & Medicinal Chemistry Letters|January 5, 1999
Potent, non-thiol inhibitors of farnesyltransferaseM J Breslin, S J deSolms, E A Giuliani, et al.Pageof 24